000 | 02007 a2200529 4500 | ||
---|---|---|---|
005 | 20250513130601.0 | ||
264 | 0 | _c19971118 | |
008 | 199711s 0 0 eng d | ||
022 | _a1073-449X | ||
024 | 7 |
_a10.1164/ajrccm.156.4.9612044 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBisgaard, H | |
245 | 0 | 0 |
_aControlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. _h[electronic resource] |
260 |
_bAmerican journal of respiratory and critical care medicine _cOct 1997 |
||
300 |
_a1190-6 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdministration, Inhalation |
650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadministration & dosage |
650 | 0 | 4 | _aBiomarkers |
650 | 0 | 4 |
_aBronchial Hyperreactivity _xdiagnosis |
650 | 0 | 4 | _aBronchial Provocation Tests |
650 | 0 | 4 |
_aBronchopneumonia _xcomplications |
650 | 0 | 4 |
_aBudesonide _xadministration & dosage |
650 | 0 | 4 | _aChild |
650 | 0 | 4 | _aChronic Disease |
650 | 0 | 4 |
_aCystic Fibrosis _xcomplications |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aForced Expiratory Flow Rates |
650 | 0 | 4 | _aHistamine |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aPseudomonas Infections _xcomplications |
650 | 0 | 4 |
_aPseudomonas aeruginosa _xisolation & purification |
650 | 0 | 4 |
_aSputum _xmetabolism |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aPedersen, S S | |
700 | 1 | _aNielsen, K G | |
700 | 1 | _aSkov, M | |
700 | 1 | _aLaursen, E M | |
700 | 1 | _aKronborg, G | |
700 | 1 | _aReimert, C M | |
700 | 1 | _aHøiby, N | |
700 | 1 | _aKoch, C | |
773 | 0 |
_tAmerican journal of respiratory and critical care medicine _gvol. 156 _gno. 4 Pt 1 _gp. 1190-6 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1164/ajrccm.156.4.9612044 _zAvailable from publisher's website |
999 |
_c9322046 _d9322046 |